Novartis Announces the European Commission approved once-daily Ultibro® Breezhaler®
September 23, 2013 |
Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® as a maintenance bronchodilator treatment to relieve symptoms in adult patients living with COPD.
"The COPD Foundation is pleased to congratulate Novartis for these approvals of Ultibro, adding another therapy to improve the lives of individuals with COPD,” John W. Walsh, president and co-founder of the COPD Foundation, says. “We look forward to licensure and access here in the United States.”